ALK and non-small cell lung carcinoma: In silico mutational modeling and docking results have been applied as a tool to predict potential utility in predicting drug responses in EGFR-mutant NSCLC,28,29BRAF-mutant NSCLC,30BRAF-mutant melanoma,31 and ALK-mutated NSCLC.32